COX-2 inhibition in cancer therapeutics: a field of controversy or a magic bullet?

Bibliography

• SUBUNGKOT S, FRAMED, LESLIE W, DRAJER D: Selective cyclo-oxygenase-2 inhibition: a target in cancer prevention and treatment. Phannacotherapy (2003) 23:9–28.
   PubMed Web of Science ®Google Scholar
• •A thorough review of COXIBs.
   Google Scholar
• SUBBARAMAIAH K, DANNENBERG AJ: Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Phannacol. Sci. (2003) 24:96–102.
   PubMed Web of Science ®Google Scholar
• •Review of the proposed mechanisms of COX-2 implication in carcinogenesis.
   Google Scholar
• UMAR A, VINER JL, ANDERSON WE HAWK ET: Development of COX inhibitors in cancer prevention and therapy. Clin. Oncol. (2003) 26(4 Suppl. 2):48–57.
   Google Scholar
• FITZGERALD GA, PATRONO C: The COXIBS, selective inhibitors of cyclooxygenase-2. New Engl." Med. (2001) 345:433–442.
   PubMed Web of Science ®Google Scholar
• •Review of the pharmaceutical status of COXIBs.
   Google Scholar
• CHAVEZ ML, DEKORTE CJ: Valdecoxib: a review. Clin. Ther: (2003) 25:817–851.
   PubMed Web of Science ®Google Scholar
• •Review commenting on current and developing COXIBs.
   Google Scholar
• GASPARINI G, LONGO R, SARMIENTO R, MORABITO A: Inhibitors of cyclo-oxygenase-2: a new class of anticancer agents? Lancet Oncol. (2003) 4:544–551.
   Google Scholar
• LANGENBACH R, LOFTIN CD, LEE C,TIANO H: Cyclooxygenase-deficient mice. A summary of their characteristics and susceptibilities to inflammation and carcinogenesis. Ann. NY Acad. Sci. (1999) 889:52–61.
   PubMed Web of Science ®Google Scholar
• BARON JA, COLE BF, SANDLER RS et al.: A randomized trial of aspirin to prevent colorectal adenomas. New Engl. J. Med. (2003) 348:891–899.
   PubMed Web of Science ®Google Scholar
• ••Clinical trial suggesting chemopreventioneffect of NSAIDs in the large bowel.
   Google Scholar
• XU XC: COX-2 inhibitors in cancer treatment and prevention, a recent development. Anticancer Drugs (2002) 13:127–137.
   PubMed Web of Science ®Google Scholar
• CHANDRASEKHARAM NV, DAI H, ROOS KL et al.: COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/ antipyretic drugs: cloning, structure, and expression. Proc. Nati Acad. Ser. USA (2002) 99:13926-13931. Identification of a new COX isoform.
   Google Scholar
• WARNER TD, MITCHELL JA: Cyclooxygenase-3 (COX-3): filling the gaps toward a COX continuum? Proc. Natl. Acad. Sci. USA (2002) 99:13371–13373.
   PubMed Web of Science ®Google Scholar
• •Important review evaluating new COX splice variants and polymorphisms.
   Google Scholar
• NIEDERBERGER E, TEGEDER I, SCHAFER C, SEEGEL M, GROSCH S, GEISSLINGER G: Opposite effects of rofecoxib on nuclear factor-KB and activating protein-1 activation. Phannacol. Exp. Ther. (2003) 304:1153–1160.
   PubMed Web of Science ®Google Scholar
• •Correlation of COXIBs and transcription factors.
   Google Scholar
• SUBBARAMAIAIH K, COLE PA, DANNENBERG AJ: Retinoids and carnosol suppress cyclooxygenase-2 transcription by CREB-binding protein/ p300-dependent and -independent mechanisms. Cancer Res. (2002) 62:2522–2530.
   PubMed Web of Science ®Google Scholar
• ••Nuclear receptors' direct and indirecteffects on COX-2 transcription.
   Google Scholar
• STOLL BA: Linkage between retinoid and fatty acid receptors: implications for breast cancer prevention. Eur. J. Cancer Prey (2002) 11:319–325.
   PubMed Web of Science ®Google Scholar
• •Cross-talk of nuclear receptors in carcinogenesis.
   Google Scholar
• KARAMOUZIS MV, GORGOULIS VG, PAPAVASSILIOU AG: Transcription factors and neoplasia: vistas in novel drug design. Clin. Cancer Res. (2002) 8:949–961.
   PubMed Web of Science ®Google Scholar
• •Focused review on the implication of transcription factors in carcinogenesis.
   Google Scholar
• KARAMOUZIS MV, PAPADAS T, VARAKIS I, SOTIROPOULOU-BONIKOU G, PAPAVASSILIOU AG: Induction of the CBP transcriptional co-activator early during laryngeal carcinogenesis. Cancer Res. Clin. Oncol. (2002) 128:135–140.
   PubMed Web of Science ®Google Scholar
• •First documented evaluation of CBP expression in human tissue.
   Google Scholar
• KARAMOUZIS MV, SOTIROPOULOU-BONIKOU G, VANDOROS G, VARAKIS I, PAPAVASSILIOU AG: Retinoid-X-receptor-a (RXR) expression during laryngeal carcinogenesis: detrimental or beneficial event? Cancer Lett. (2003) 199:175–183.
   Google Scholar
• •Proposed indirect mechanism of COX-2 overexpression during carcinogenesis.
   Google Scholar
• YU HP, XU SQ, LIU L et al: Cyclooxygenase-2 expression in squamous dysplasia and squamous cell carcinoma of the esophagus. Cancer Lett. (2003) 198:193–201.
   PubMed Web of Science ®Google Scholar
• SONG SH, JONG HS, CHOI HH et al.: Transcriptional silencing of cyclooxygenase-2 by hyper-methylation of the 5' CpG island in human gastric carcinoma cells. Cancer Res. (2001) 61:4628–4635.
   PubMed Web of Science ®Google Scholar
• •Outlines the importance of epigenetics in carcinogenesis.
   Google Scholar
• TACCONELLI S, CAPONE ML, SCIULLI MG, RICCIOTTI E, PATRIGNANI P: The biochemical selectivity of novel COX-2 inhibitors in whole blood assays of COX-isoenzyme activity. Carr. Med. Res. Opin. (2002) 18:503–511.
   PubMed Web of Science ®Google Scholar
• CRONSTEIN BN: Cyclooxygenase-2-selective inhibitors: translating pharmacology into clinical utility. Cleve. Clin. J. Med. (2002) 69\(Suppl. 1):113–119.
   Google Scholar
• •Pharmacological issues concerning COXIBs.
   Google Scholar
• SARAPA N, BRITTO MR, COTTON B et al.: Valdecoxib, a COX-2-specific inhibitor, does not affect cardiac depolarization. Clin. Phannacol. (2003) 43:974–982.
   Web of Science ®Google Scholar
• •Evaluation of clinical safety of valdecoxib.
   Google Scholar
• DALLOB A, HAWKEY CJ, GREENBERG H et al.: Characterization of etoricoxib, a novel, selective COX-2 inhibitor. J. Clin. Phannacol. (2003) 43:573–585.
   Web of Science ®Google Scholar
• •Etoricoxib: a new selective COX-2 inhibitor.
   Google Scholar
• BOMBARDIER C, LAINE L, REICIN A et al.: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. New Engl. J. Med. (2000) 343:1520–1528.
   PubMed Web of Science ®Google Scholar
• ••Clinical trial that verified thegastrointestinal safety of rofecoxib.
   Google Scholar
• SILVERSTEIN F, FAICH G, GOLDSTEIN JL et al: Gastrointestinal toxicity with celecoxib versus nonsteroidal anti-inflammatory drugs for osteoasrthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. JAMA (2000) 284:1247–1255.
   PubMed Web of Science ®Google Scholar
• ••Clinical trial that verified thegastrointestinal safety of celecoxib.
   Google Scholar
• MacDONALD TM, MORANT SV, GOLDSTEIN JL, BURKE TA, PETTITT D: Channeling bias and the incidence of gastrointestinal hemorrhage in users of meloxicam, coxibs, and older, non-specific non-steroidal anti-inflammatory drugs. Gut (2003) 52:1265–1270.
   PubMed Web of Science ®Google Scholar
• WOLFE MM: Risk factors associated with the development of gastroduodenal ulcers due to the use of NSAIDs. Int." Clin. Pract. Sapp]. (2003) 135:32–37.
   PubMedGoogle Scholar
• KONSTAM ME, WEIR MR: Current perspectives on the cardiovascular effects of coxibs. Cleve. Clin. J. Med. (2002) 69\(Suppl. 1):147–152.
   Google Scholar
• CHIOLERO A, MAILLARD MP, BURNIER M: Cardiovascular hazard of selective COX-2 inhibitors: myth or reality? Expert Opin. Drug Sal (2002) 1:45–52.
   Google Scholar
• •Discussion on cardiovascular toxicity profile of COX-2 inhibitors.
   Google Scholar
• PERAZELLA MA: COX-2 selective inhibitors: analysis of the renal effects. Expert Opin. Drug Sal (2002) 1:53–64.
   PubMedGoogle Scholar
• •Discussion on renal toxicity profile of COX-2 inhibitors.
   Google Scholar
• ZHA S, GAGE WR, SAUVAGEOT Jet al.: Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma. Cancer Res. (2001) 61:8617–8623.
   Google Scholar
• •Study arguing COX-2 overexpression in cancer tissues compared to normal.
   Google Scholar
• SUBBARAYAN V, SABICHI AL, LIANSA N, LIPPMAN SM, MENTER DG: Differential expression of cyclooxygenase-2 and its regulation by tumor necrosis factor-a in normal and malignant prostate cells. Cancer Res. (2001) 61:2720–2726.
   PubMed Web of Science ®Google Scholar
• LIU CH, CHANG SH, NARKO K et al.: Over-expression of cyclooxygenase (Cox)-2 is sufficient to induce tumorigenesis in transgenic mice. Biol. Chem. (2001) 276:18563–18569.
   Web of Science ®Google Scholar
• ••Evidence of COX-2 implication in breastcarcinogenesis in transgenic mice.
   Google Scholar
• MULLER-DECKER K, NEUFANG G, BERGER I, NEUMANN M, MARKS F, FURSTENBERGER G: Transgenic cyclooxygenase-2 overexpression sensitizes mouse skin for carcinogenesis. Proc. Nati Acad. Sci. USA (2002) 99:12483–12488.
   PubMed Web of Science ®Google Scholar
• ••Evidence of COX-2 implication in skincarcinogenesis in transgenic mice.
   Google Scholar
• BOL DK, ROWLEY RB, HO CP et al.: Cyc1ooxygenase-2 overexpression in the skin of transgenic mice results in suppression of tumor development. Cancer Res. (2002) 62:2516–2521.
   PubMed Web of Science ®Google Scholar
• ••First report debating COX-2 implicationin carcinogenesis.
   Google Scholar
• TIANO HF, LOFTIN CD, AKUNDA J et al.: Deficiency of either cyclooxygenase (COX)-1 or COX-2 alters epidermal differentiation and reduces mouse skin tumorigenesis. Cancer Res. (2002) 62:3395–3401.
   PubMed Web of Science ®Google Scholar
• ••Knockout experiments outlining COX-2implication in carcinogenesis.
   Google Scholar
• WIESE FW, THOMPSON PA, KADLUBAR FF: Carcinogen substrate specificity of human COX-1 and COX-2. Carcinogenesis (2001) 22:5–10.
   PubMed Web of Science ®Google Scholar
• •COX-2 and xenobiotic metabolism.
   Google Scholar
• TOTZKE G, SCHULZE-OSTHOFF K, JANICKE RU: Cyclooxygenase-2 (COX-2) inhibitors sensitize tumor cells specifically to death receptor-induced apoptosis independently of COX-2 inhibition. Oncogene (2003) 22:6077–6086.
   Google Scholar
• ••Apoptosis and COX-2 inhibition incarcinogenesis.
   Google Scholar
• LIM SC: Role of COX-2, VEGF, and cyclin D1 in mammary infiltrating duct carcinoma. Oncol. Rep. (2003) 10:1241–1249.
   PubMed Web of Science ®Google Scholar
• MASFERRERJL: Approach to angiogenesis inhibition based on cyclooxygeanse-2. Cancer (2002) 7\(Supp1.3):44–50.
   Google Scholar
• ••COX-2 inhibition and angiogenesis incarcinogenesis.
   Google Scholar
• DAVIES G, MARTIN LA, SACKS N, DOWSETT M: Cyclooxygenase-2 (COX-2), aromatase and breast cancer: a possible role for COX-2 inhibitors in breast cancer chemoprevention. Ann. Oncol (2002) 13:669–678.
   PubMed Web of Science ®Google Scholar
• ••COX-2 enhances aromatase activity inbreast cancer.
   Google Scholar
• PATEL VA, DUNN MJ, SOROKIN A: Regulation of MDR-1 (P-glycoprotein) by cyclooxygenase-2. .1 Biol. Chem. (2002) 277:38915–38920.
   PubMed Web of Science ®Google Scholar
• ••COX-2 upregulation is correlated withchemotherapy resistance.
   Google Scholar
• CAO Y, PRESCOTT SM: Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. .1 Cell Physiol. (2002) 190:279–286.
   PubMed Web of Science ®Google Scholar
• STEINBACH G, LYNCH PM, PHILLIPS RK et al.: The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. New Engl. J. Med. (2000) 342:1946–1952.
   PubMed Web of Science ®Google Scholar
• ••Celecoxib reduces the number of adenomatous polyps in FAP patients.
   Google Scholar
• HALLAK A, ALON-BARON L, SHAMIR R et al.: Rofecoxib reduces polyp recurrence in familial polyposis. Dig. Dis. Sci. (2003) 48:1998–2002.
   PubMed Web of Science ®Google Scholar
• BLANKE CD, BENSON AB, DRAGOVICH T et al.:A Phase II study of celecoxib (CX), irinotecan (I), 5-fluorouracil (5FU), and leukovorin (LCV) in patients (pts) with unresectable or metastatic colorectal cancer (CRC). Proc. Am. Soc. Clin. Oncol (2002) Abstract 505.
   Google Scholar
• •Celecoxib and chemotherapy combination in metastatic colorectal cancer.
   Google Scholar
• CAPONE ML, TACCONELLI S, SCIULU MG, PATRIGNANI P Clinical pharmacology of selective COX-2 inhibitors. bit. j kifnunopathol. Pharmacol. (2003) 16\(Suppl. 2):49–58.
   Google Scholar
• CHURCH RD, FLESHMAN JW, MCLEOD HL: Cyclooxygenase 2 inhibition in colorectal cancer therapy. Br." Surg. (2003) 90:1055–1067.
   PubMed Web of Science ®Google Scholar
• GROVER JK, YADAV S, VATS V, JOSHI YK: Cyclo-oxygenase-2 inhibitors: emerging roles in the gut. Int. J. Colorectal. Dis. (2003) 18:279–291.
   PubMed Web of Science ®Google Scholar
• TRIFAN OC, DURHAM WE SALAZAR VS et al.: Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11. Cancer Res. (2002) 62:5778–5784.
   Google Scholar
• ••Evidence of COXIBs' role in amelioratingchemotherapy-induced diarrhoea.
   Google Scholar
• BECERRA CR, FRENKEL EP, ASHFAQ R, GAYNOR RB: Increased toxicity and lack of efficacy of rofecoxib in combination with chemotherapy for treatment of metastatic colorectal cancer: a Phase II study. Int. J. Cancer (2003) 105:868–872.
   PubMed Web of Science ®Google Scholar
• ••Rofecoxib does not enhance chemotherapyeffect in metastatic colon cancer.
   Google Scholar
• KASE S, OSAKI M, HONJO S et al.: Expression of cyclo-oxygenase-2 is correlated with high intratumoral microvessel density and low apoptotic index in human esophageal squamous cell carcinomas. Virchows Arch. (2003) 442:129–135.
   PubMed Web of Science ®Google Scholar
• WILSON KT: Angiogenic markers, neovascularization and malignant transformation of Barrett's esophagus. Dis. Esophagus (2002) 15:16–21.
   PubMed Web of Science ®Google Scholar
• J00 YE, REW JS, SEO YH et al: Cyclooxygenase-2 overexpression correlates with vascular endothelial growth factor expression and tumor angiogenesis in gastric cancer. Clin. Castroenterol (2003) 37:28–33.
   PubMed Web of Science ®Google Scholar
• RICH TA, SHEPARD R: COX-2 inhibitors as radiation sensitizers for upper GI tract cancers: esophagus, stomach and pancreas. Am. J. Clin. OncoL (2003) 26(4 Supp1.2):110–113.
   Google Scholar
• •COXIBs may enhance radiation activity in gastrointestinal tumours.
   Google Scholar
• KONTUREK PC, KANIA J, KONTUREK JW, NIKIFORUK A, KONTUREK SJ, HAHN EG: H pylori infection, atrophic gastritis, cytokines, gastrin, COX-2, PPARy and impaired apoptosis in gastric carcinogenesis. Med. Sci. Monit. (2003) 9:53–66.
   Google Scholar
• •COX-2 and H pylori correlation in gastric carcinogenesis.
   Google Scholar
• CHU J, LOYD FL, TRIFAN QC, KNAPP B, RIZZO MT: Potential involvement of the cyclooxygenase-2 pathway in the regulation of tumor-associated angiogenesis and growth in pancreatic cancer. MoL Cancer The]: (2003) 2:1–7.
   PubMed Web of Science ®Google Scholar
• CRANE CH, MASON K, JANJAN NA, MILAS L: Initial experience combining cyclooxygenase-2 inhibition with chemoradiation for locally advanced pancreatic cancer. Am. Clin. Oncol (2003) 26(4 Supp12):81–84.
   Google Scholar
• •COXIBs and chemoradiation in pancreatic cancer preliminary results.
   Google Scholar
• SMITH SE, BURRIS HA, LOEHRER PJ et al.: Preliminary results of a Phase II trial of gemcitabine combined with celecoxib for advanced pancreatic cancer. Proc. Am. Soc. Clin. Oncol (2003) 22:374 (Abstract 1502).
   Google Scholar
• •First clinical trial of celecoxib and chemotherapy in pancreatic cancer.
   Google Scholar
• KOGA H: Hepatocellular carcinoma: is there a potential for chemoprevention using cyclooxygenase-2 inhibitors? Cancer (2003) 98:661–667.
   PubMed Web of Science ®Google Scholar
• CHENG AS, CHAN HL, LEUNG WK, WONG N, JOHNSON PJ, SUNG JJ: Specific COX-2 inhibitor, NS-398, suppresses cellular proliferation and induces apoptosis in human hepatocellular carcinoma cells. Int. J Oncol (2003) 23:113–119.
   PubMed Web of Science ®Google Scholar
• TREIBER G, HEINRICH U, FOSTITSCH P, ROEKEN C, MALFERTHEINER P Palliative treatment of hepatocellular carcinoma (HCC) using octreotide, rofecoxib, or both. Proc. Am. Soc. Clin. Oncol (2003) 22:319. (Abstract 1281).
   Google Scholar
• •First clinical trial evaluating celecoxib in hepatocellular carcinoma treatment.
   Google Scholar
• HARA S, KONDO Y, MATSUZAWA I et al.: Expression of cyclooxygenase-2 in human bladder and renal cell carcinoma. Adv. Exp. Med. Biol. (2002) 507:123–126.
   PubMed Web of Science ®Google Scholar
• •Differential expression of COX-2 in genitourinary tract cancers.
   Google Scholar
• SHARIAT SF, MATSUMOTO K, KIM J et al.: Correlation of cyclooxygenase-2 with molecular markers, pathological features and clinical outcome of transitional cell carcinoma of the bladder.' Ural. (2003) 170:985–989.
   PubMed Web of Science ®Google Scholar
• SHEEHY OE, ZHAO SZ, RAYMOUNDO AL et al.: Celecoxib associated with reduced risk of superficial bladder cancer (SBC). Proc. Am. Soc. Chi]. Oncol (2003) 22:383 (Abstract 1539).
   Google Scholar
• ••NSAIDs and celecoxib reduce the risk of superficial bladder cancer recurrence.
   Google Scholar
• PRUTHI RS, DERKSEN E, GASTON K: Cyclooxygenase-2 as a potential target in the prevention and treatment of genitourinary tumors: a review." UroL (2003) 169:2352–2359.
   PubMed Web of Science ®Google Scholar
• •Review focusing on COX-2 expression in the genitourinary tract.
   Google Scholar
• HUSSAIN T, GUPTA S, MUNHTAR H. Cyclooxygenase-2 and prostate carcinogenesis. Cancer Lett. (2003) 191:121–135.
   Google Scholar
• LEACH R, POLLOCK B, BASLER J, TROYER D, NAYLOR S, THOMSON IM: Chemoprevention of prostate cancer: Focus on key opportunities and clinical trials UroL Clin. North Am. (2003) 30:227–237.
   Web of Science ®Google Scholar
• PAPATSORIS AG, PAPAVASSILIOU AG: Prostate cancer: horizons in the development of novel anti-cancer agents. Curr. Med. Chem. Anti-Canc. Agents (2001) 1:47–70.
   PubMedGoogle Scholar
• •Insights in the era of new biological agents for prostate cancer treatment.
   Google Scholar
• WATANABE 0, SHIMIZU T, IMAMURA H et al.: Expression of cyclooxygenase-2 in malignant and benign breast tumors. Anti-Cancer Res. (2003) 23:3215–3221.
   Google Scholar
• •Differential expression of COX-2 during breast carcinogenesis.
   Google Scholar
• SINGH-RANGER G. MOKBEL K: Current concepts in cyclooxygenase inhibition in breast cancer. Clin. Pharm. Thec (2002) 27:321–327.
   PubMed Web of Science ®Google Scholar
• SUBBARAMAIAH K, NORTON L, GERALD W, DANNENBERG AJ: Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer. Evidence for involvement of AP-1 and PEA3. Biol. Chem. (2002) 277:18649–18657.
   Google Scholar
• ••COX-2 overexpression is correlated withHER-2 positivity in breast cancers.
   Google Scholar
• DANG CT, DICKLER MN, MOASSER MM, THEODOULOU M, SEIDMAN A: Celecoxib (C) and trastuzumab (herceptin) (H) is feasible after H for HER-2/neu overexpressing (H2+) metastatic breast cancer (MBC) patients (pts). Proc. AM. Soc. Clin. Oncol (2002) (Abstract 2003).
   Google Scholar
• CHOW LW, WONG JL, TOI M: Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer: preliminary report. Steroid Biochem. MM. Biol. (2003) 86:443–447.
   PubMed Web of Science ®Google Scholar
• •Clinical results of aromatase inhibitors and celecoxib in breast cancer.
   Google Scholar
• CANNEY PA: A Phase II study of the efficacy and tolerability of the combination of exemestane with the cyclooxygenase-2 inhibitor celecoxib in postmenopausal patients with advanced breast cancer. Proc. Am. Soc. Clin. Oncol (2003) 22:40 (Abstract 158).
   Google Scholar
• DIRIX LY, IGNACIO J, NAG S et al: Final results from an open-label, multicenter, controlled study of exemestane +/- celecoxib in postmenopausal women with advanced breast cancer (ABC) progressed on tamoxifen (T). Proc. Am. Soc. Clin. Oncol (2003) 22:20 (Abstract 77).
   Google Scholar
• SUBBARAMAIAH K, HART JC, NORTON L et al: Microtubule-interfering agents stimulate the transcription of cyclooxygenase-2: evidence for involvement of ERK1/2 and p38 mitogen-activated protein kinase pathways. j Biol. Chem. (2000) 275:14838–14845.
   PubMed Web of Science ®Google Scholar
• •Evidence for in vivo synergism of COXIBs and tubulin-interfering agents.
   Google Scholar
• CHOW LW, TOI M, TAKEBAYASHI Y: Neoadjuvant celecoxib and 5-fluorouracil/ epirubicin/cyclophosphamide (FEC) for the treatment of locally advanced breast cancer (LABC). Proc. Am. Soc. Clin. Oncol (2003) 22:82 (Abstract 327).
   Google Scholar
• LANDEN CN JR, MATHUR SP, RICHARDSON MS, CREASMAN WT:
   Google Scholar
• •• Expression of cyclooxygenase-2 in cervical, endometrial, and ovarian malignancies. Am. J. Obstet. GynecoL (2003) 188:1174-1176. COX-2 expression in gynaecological tumours.
   Google Scholar
• FERRANDINA G, RANELLETTI FO, LAURIOLA L et al.: Cyclooxygenase-2 (COX-2), epidermal growth factor receptor (EGER), and HER-2/neu expression in ovarian cancer. Gynecol Oncol (2002) 85:305–310.
   PubMed Web of Science ®Google Scholar
• FERRANDINA G, LAURIOLA L, ZANNONI GF et al.: Increased cyclooxygenase-2 (COX-2) expression is associated with chemotherapy resistance and outcome in ovarian cancer patients. Ann. OncoL (2002) 13:1205–1211.
   PubMed Web of Science ®Google Scholar
• ••COX-2 expression might serve as a predictive factor of chemotherapy outcome.
   Google Scholar
• GRIDELLI C, MAIONE P, AIROMA G, ROSSI A: Selective cyclooxygenase-2 inhibitors and non-small cell lung cancer. Curr: Med. Chem. (2002) 9:1851–1858.
   Google Scholar
• GARDNER B, ZHU LX, SHARMA S, TASHKIN DP, DUBINETT SM: Methanandamide increases COX-2 expression and tumor growth in murine lung cancer. FASEB (2003) (Epub ahead of print).
   Google Scholar
• RICHARDSON CM, SHARMA RA, COX G, O'BYME KJ: Epidermal growth factor receptors and cyclooxygenase-2 expression in the pathogenesis of non-small cell lung cancer: potential targets for chemoprevention and systemic therapy. Lung Cancer (2003) 39:1–13.
   PubMed Web of Science ®Google Scholar
• •Proposed combined use of COXIBS and anti-EGFR agents in lung cancer.
   Google Scholar
• VOKES EE, CHOY H: Targeted therapiesfor stage III non-small cell lung cancer: integration in the combined modality setting. Lung Cancer (2003) 41\(Supp1.11):115–121.
   Google Scholar
• LIAO Z, MILAS L, KOMAKI R, STEVENS C, COX JD: Combination of a COX-2 inhibitor with radiotherapy or radiochemotherapy in the treatment of thoracic cancer. Am. J. Gin. Oncol (2003) 26(4 Suppl. 2):85–91.
   Google Scholar
• STANI SC, MANSUETO G, COMELLA G et al.: Antiangiogenic therapy with celecoxib and weekly paclitaxel as second line treatment for advanced non small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol (2003) 22:687 (Abstract 2763).
   Google Scholar
• NUGENT FW, GRAZIANO S, LEVITAN N, COLLEA R et a/.: Docetaxel and COX-2 inhibition with celecoxib in relapsed/refractory non-small cell lung cancer (NSCLC): promising progression-free survival in a Phase II study. Proc. Am. Soc. Clin. OncoL (2003) 22: 671 (Abstract 2697).
   Google Scholar
• GADGEEL SM, THATAI L, KRAUT M et al.: Phase II study of celecoxib and docetaxel in non-small cell lung cancer (NSCLC) patients with progression after platinum-based therapy. Proc. Am. Soc. Clin. Oncol (2003) 22:683 (Abstract 2749).
   Google Scholar
• SHEHADEH NJ, KALEMKERIAN GP, WOZNIAK A et al.: Preliminary results of a Phase II study of celecoxib and weekly docetaxel in elderly or PS2 patients with advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. OncoL (2003) 22:686 (Abstract 2758).
   Google Scholar
• UN DT, SUBBARAMAIAH K, SHAH JP, DANNENBERG AJ, BOYLE JO: Cyclooxygenase-2: a novel molecular target for the prevention and treatment of head and neck cancer. Head Neck (2002) 24:792–799.
   PubMed Web of Science ®Google Scholar
• HASHITANI S, URADE M, NISHIMURA N et al.: Apoptosis induction and enhancement of cytotoxicity of anticancer drugs by celecoxib, a selective cyclooxygenase-2 inhibitor, in human head and neck carcinoma cell lines. Int. J. Oncol (2003) 23:665–672.
   PubMed Web of Science ®Google Scholar
• •In vitro evidence for COXIBs' mechanism of action in head and neck cancers.
   Google Scholar
• BRECHER AR: The role of cyclooxygenase-2 in the pathogenesis of skin cancer. J. Drugs Dermatol (2002) 1:44–47.
   PubMedGoogle Scholar
• •COX-2 expression and skin cancers.
   Google Scholar
• DUFF M, STAPLETON PP, MESTRE JR et al.: Cyclooxygenase-2 inhibition improves macrophage function in melanoma and increases the antineoplastic activity of interferon gamma. Ann. Stow. Oncol (2003) 10:305–313.
   PubMed Web of Science ®Google Scholar
• SHONO T, TOFILON PJ, BRUNER JM, OWOLABI 0, LANG FF: Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular connections. Cancer Res. (2003) 61:4375–4381.
   Web of Science ®Google Scholar
• •COX-2 expression and brain tumours.
   Google Scholar
• JOKI T, HEESE 0, NIKAS DC et al.: Expression of cyclooxygenase-2 (COX-2) in human glioma and M vitro inhibition by a specific COX-2 inhibitor, NS-398. Cancer Res. (2000) 60:4926–4931.
   Google Scholar
• PHILLIPS RKS, WALLACE MH, LYNCH PM et at A randomized, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut (2002) 50:857–860.
   PubMed Web of Science ®Google Scholar
• •Celecoxib activity on duodenal polyposis in FAP patients.
   Google Scholar
• DICKER AP: COX-2 inhibitors and cancer therapeutics: potential roles for inhibitors of COX-2 in combination with cytotoxic therapy. Am. J. Clin. OncoL (2003) (4 Supp1.2):46–47.
   Google Scholar
• MILLER KD, SWEENEY CJ, SLEDGE GW JR: Redefining the target: chemotherapeutics as antiangiogenesis. J. Gin. Oncol (2001) 19:1195–1206.
   Web of Science ®Google Scholar
• ••COXIBs as antiangiogenesis agents.
   Google Scholar
• ANDERSON WE UMAR A, VINER JL, HAWK ET: The role of cyclooxygenase inhibitors in cancer prevention. Curl: Pharm. Des. (2002) 8:1035–1062.
   PubMed Web of Science ®Google Scholar
• •Current perspectives of COXIBs in chemoprevention.
   Google Scholar
• HIDA T, KOZAKI KI, MURAMATSU H et al.: Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines. Clin. Cancer Res. (2000) 6:2006–2011.
   PubMed Web of Science ®Google Scholar
• KNAPP DW, GLICKMAN NW, WIDMER WR et al.: Cisplatin versus ciplatin combined with piroxicam in a canine model of human invasive urinary bladder cancer. Cancer Chemother. Pharmacol (2000) 46:221–226.
   PubMed Web of Science ®Google Scholar
• YIP-SCNEIDER MT, SWEENEY CJ, JUNG SH et al: Cell cycle effects of nonsteroidal anti-inflammatory drugs and enhanced growth inhibition in combination with gemcitabine in pancreatic carcinoma cells. J. Pharmacol Exp. The]: (2001) 298:976–985.
   PubMed Web of Science ®Google Scholar
• ALTORKI NK, KORESZTES RS, PORT JL et al.: Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer. Clin. OncoL (2003) 21:2645–2650.
   Web of Science ®Google Scholar
• ••Clinical trial with COXIBs efficacy in earlycancer treatment.
   Google Scholar
• MILAS L: Cyclooxygenase-2 (COX-2) enzyme inhibitors and radiotherapy. Am. J. Oncol (2003) 26(4 Suppl. 2):66–69.
   Google Scholar
• GAFFNEY DK, HOLDEN J, DAVIS M et al.: Elevated cyclooxygenase-2 expression correlates with diminished survival in 371 Expert Op/n. Investig. Drugs (2004) 13(4) Affiliation Michalis V Karamouzis12 & Athanasios G Papavassiliouti -rAuthor for correspondence -"Department of Biochemistry, University of Patras, School of Medicine, 26110 Patras, Greece 21st Department of Medical Oncology, 'St Savvas' Anticancer-Oncologic Hospital, Athens, Greece Fax: +32 610 996110; E-mail: [email protected] carcinoma of the cervix treated with radiotherapy. Int. .1. Radiat. Oncol. Biol. Phys. (2001) 49:1213-1217. •COX-2 expression as prognostic marker in patients under radiotherapy.
   Google Scholar
• PETERSEN C, PETERSEN S, MILAS L et al.: Enhancement of intrinsic tumor cell radiosensitivity induced by a selective cyclooxygenase-2 inhibitor. Clin. Cancer Res. (2000) 6:2413–2420.
   Google Scholar
• •COX-2 inhibition enhances cancer cell radiosensitivity.
   Google Scholar
• MacDONALD JS, SMALLEY SR, BENEDETTI J et al.: Chemotadiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. New Engl. J. Med. (2001) 345:725–730.
   PubMed Web of Science ®Google Scholar
• BADAWI AF, BADR MZ: Chemoprevention of breast cancer by targeting cyclooxygenase-2 and peroxisome proliferators-activated receptor-y. hat. J. Oncol. (2002) 20:1109–1122.
   Web of Science ®Google Scholar
• •Proposal for combined use of targeted agents in breast cancer treatment.
   Google Scholar
• MENTER DG: Cyclooxygenase-2 selective inhibitors in cancer treatment and prevention. Expert Opin. Investig. Drugs (2002) 11:1749–1764.
   PubMed Web of Science ®Google Scholar